September 2024

A comparison of the safety and efficacy of tapinarof and roflumilast topical therapies in the management of mild-to-moderate plaque psoriasis

Skin Res Technol. 2024 Sep;30:e70041 doi: 10.1111/srt.70041

Ghani et al. compared the efficacy and safety profiles of tapinarof and roflumilast for treating mild-to-moderate plaque psoriasis. Both therapies showed robust efficacy and were well-tolerated, with low rates of adverse events. Tapinarof exhibited marginally higher efficacy in PASI scores compared to roflumilast.

Keywords:

A multicentre randomized double-blind placebo-controlled phase III study of the efficacy and safety of xeligekimab (GR1501) in patients with moderate-to-severe plaque psoriasis

Br J Dermatol. 2024 Aug 14;191:336-343 doi:10.1093/bjd/ljae062

Cai et al. demonstrated that xeligekimab significantly improved the Psoriasis Area and Severity Index (PASI) scores in patients with moderate-to-severe plaque psoriasis, with 90.7% achieving PASI 75 at week 12. Xeligekimab was well-tolerated with no unexpected safety concerns.

Keywords:

Efficacy and Safety of Intravenous Secukinumab in Patients With Active Axial Spondyloarthritis: Results From the Randomized, Placebo-Controlled, Phase III INVIGORATE-1 Study

Arthritis Rheumatol. 2024 Sep 19 doi 10.1002/art.42993 Epub ahead of print

Deodhar et al. evaluated the efficacy and safety of intravenous secukinumab in patients with active axial spondyloarthritis. The study found a significant improvement in the ASAS40 response at Week 16 (40.9% vs 22.9% in placebo, P<0.0001), with responses maintained through Week 52. No new safety signals were observed.

Keywords:

Efficacy and safety of intravenous secukinumab for the treatment of active psoriatic arthritis: Results from the randomized, placebo-controlled Phase III INVIGORATE-2 study

Arthritis Rheumatol 2024 doi: 10.1002/art.42997

IV secukinumab provided rapid and sustained improvements in disease signs and symptoms at Week 16 and through 52 weeks. Kivitz et al. evaluated the long-term efficacy, safety, and tolerability of IV secukinumab in patients with active PsA.

Keywords:

Janus kinase inhibitors versus tumour necrosis factor inhibitors in rheumatoid arthritis: meta-analytical comparison of efficacy and safety

Inflammopharmacology (2024) 32:3229–46 doi: 10.1007/s10787-024-01563-3

Kandeel et al. compared JAK inhibitors and TNF inhibitors in RA. JAK inhibitors demonstrated better functional improvement via HAQ-DI but showed insignificant difference in CDAI compared to TNF inhibitors; both classes had similar safety.

Keywords:

August 2024

A secukinumab dose-escalation study in patients with ankylosing spondylitis not achieving inactive disease after 16 weeks of treatment

Rheum 2024 doi: 10.1093/rheumatology/keae432 Epub ahead of print

Deodhar et al. investigated the impact on efficacy and safety of escalating secukinumab dose from 150mg to 300mg Q4W in AS patients who did not achieve inactive disease during an initial 16-week period of 150mg secukinumab. At Week 52, clinical safety response rates were similar across groups continuing with 150mg or escalating to 300mg secukinumab.

Keywords:

Efficacy and safety of current therapies for difficult-to-treat rheumatoid arthritis: a systematic review and network meta-analysis

Journal of Translational Medicine 2024;22:795

Su et al. conducted a comprehensive systematic review and network meta-analysis to assess the efficacy and safety of therapies for difficult-to-treat (D2T) RA. They found that tocilizumab and rituximab had superior efficacy and safety profiles, with 8mg every 4 weeks of tocilizumab identified as the optimal therapeutic dose.

Keywords:

Efficacy and safety of etrasimod in patients with moderately to severely active isolated proctitis: Results from the Phase 3 ELEVATE UC clinical programme

JJC 2024;18;391(3):2170 82. DOI 10.1093/ecco-jcc/jjae038

Peyrin-Biroulet et al. evaluated the efficacy and safety of etrasimod in patients with moderately to severely active isolated proctitis, demonstrating significant improvement in clinical outcomes compared to placebo. The study reported a favourable safety profile, making etrasimod a viable treatment option for this population.

Keywords:

July 2024

Efficacy and Safety of Bimekizumab in Patients with Psoriatic Arthritis With or Without Methotrexate: 52-Week Results From Two Phase 3 Studies

ACR Open Rheumatol. 2024 Jul 30 doi: 10.1002/acr2.11727 Epub ahead of print

McInnes et al. reported that bimekizumab demonstrated sustained efficacy and safety over 52 weeks in patients with psoriatic arthritis (PsA), regardless of concomitant methotrexate (MTX) use. Both bimekizumab groups (with and without MTX) showed similar improvements in achieving ACR50 and PASI100 responses.

Keywords:

Upadacitinib monotherapy versus methotrexate monotherapy in patients with rheumatoid arthritis: efficacy and safety through 5 years in the SELECT-EARLY randomized controlled trial

Journal Reference: Arthritis Res Ther 2024;26:143 doi: 10.1186/s13075-024-03358-x

van Vollenhoven et al. compared the efficacy and safety of upadacitinib monotherapy to methotrexate monotherapy over five years in methotrexate-naïve patients with rheumatoid arthritis. The study found that upadacitinib provided better long-term efficacy and higher rates of disease activity remission than methotrexate; however, it was associated with higher incidences of adverse events, particularly at the higher dose of 30 mg.

Keywords: